MD Anderson Cancer Center

The University of Texas

Houston, TX

Sorting 4 by

Accepting patients

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

SUCCESSOR-1

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER-Maintenance

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Learn more
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1